Oliviero Riggio

List of Publications by Year
in descending order

286	11,716	20797 60	31818 101
papers	citations	h-index	g-index

299	299	299	6860
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	ESPEN Guidelines on Enteral Nutrition: Liver disease. Clinical Nutrition, 2006, 25, 285-294.	2.3	616
2	Incidence and natural history of small esophageal varices in cirrhotic patients. Journal of Hepatology, 2003, 38, 266-272.	1.8	466
3	Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet, The, 2018, 391, 2417-2429.	6.3	345
4	Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology, 2004, 40, 629-635.	3.6	327
5	Does malnutrition affect survival in cirrhosis?. Hepatology, 1996, 23, 1041-1046.	3.6	315
6	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. Journal of Hepatology, 2020, 73, 842-854.	1.8	282
7	Cirrhotic Patients Are at Risk for Health Careâ€“Associated Bacterial Infections. Clinical Gastroenterology and Hepatology, 2010, 8, 979-985.e1.	2.4	274
8	MELD score is better than Childâ€“Pugh score in predicting 3-month survival of patients undergoing transjugular intrahepatic portosystemic shunt. Journal of Hepatology, 2002, 36, 494-500.	1.8	248
9	Incidence, Natural History, and Risk Factors of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt With Polytetrafluoroethylene-Covered Stent Grafts. American Journal of Gastroenterology, 2008, 103, 2738-2746.	0.2	239
10	Nutritional status: its influence on the outcome of patients undergoing liver transplantation. Liver International, 2010, 30, 208-214.	1.9	233
11	Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. Journal of Hepatology, 2005, 42, 674-679.	1.8	202
12	Muscle depletion increases the risk of overt and minimal hepatic encephalopathy: results of a prospective study. Metabolic Brain Disease, 2013, 28, 281-284.	1.4	201
13	Antithrombotic treatment with directâ€acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. Liver International, 2017, 37, 694-699.	1.9	178
14	Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: A randomized multicenter trial. Hepatology, 1998, 27, 48-53.	3.6	172
15	High prevalence of spontaneous portal-systemic shunts in persistent hepatic encephalopathy: A case-control study. Hepatology, 2005, 42, 1158-1165.	3.6	164
16	Branched-chain amino acids vs lactulose in the treatment of hepatic coma. Digestive Diseases and Sciences, 1982, 27, 929-935.	1.1	157
17	Sarcopenia Is Risk Factor for Development of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt Placement. Clinical Gastroenterology and Hepatology, 2017, 15, 934-936.	2.4	150
18	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. Journal of Hepatology, 2021, 74, 1097-1108.	1.8	149

#	Article	IF	Citations
19	Basal energy production rate and substrate use in stable cirrhotic patients. Hepatology, 1990, 12, 106-112.	3.6	147
20	The animal naming test: An easy tool for the assessment of hepatic encephalopathy. Hepatology, 2017, 66, 198-208.	3.6	135
21	Modification of cardiac function in cirrhotic patients with and without ascites. American Journal of Gastroenterology, 2000, 95, 3200-3205.	0.2	133
22	Polytetrafluoroethylene-covered Nitinol Stent-Graft for Transjugular Intrahepatic Portosystemic Shunt Creation: 3-year Experience. Radiology, 2004, 231, 820-830.	3.6	129
23	Clinical efficacy of transjugular intrahepatic portosystemic shunt created with covered stents with different diameters: Results of a randomized controlled trial. Journal of Hepatology, 2010, 53, 267-272.	1.8	129
24	Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Digestive Diseases and Sciences, 1996, 41, 578-584.	1.1	127
25	Malnutrition is a risk factor in cirrhotic patients undergoing surgery. Nutrition, 2002, 18, 978-986.	1.1	127
26	Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt. Clinics in Liver Disease, 2012, 16, 133-146.	1.0	122
27	Short-term oral zinc supplementation does not improve chronic hepatic encephalopathy. Digestive Diseases and Sciences, 1991, 36, 1204-1208.	1.1	121
28	Role of determination of partial pressure of ammonia in cirrhotic patients with and without hepatic encephalopathy. Journal of Hepatology, 2003, 38, 441-446.	1.8	119
29	Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS. Gut, 2011, 60, 1389-1393.	6.1	111
30	Lowâ€grade endotoxemia and platelet activation in cirrhosis. Hepatology, 2017, 65, 571-581.	3.6	107
31	Muscle Alterations Are Associated With Minimal and Overt Hepatic Encephalopathy in Patients With Liver Cirrhosis. Hepatology, 2019, 70, 1704-1713.	3.6	105
32	Evidence of Persistent Cognitive Impairment After Resolution of Overt Hepatic Encephalopathy. Clinical Gastroenterology and Hepatology, 2011, 9, 181-183.	2.4	99
33	Modifications of cardiac function in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt (TIPS). American Journal of Gastroenterology, 2002, 97, 142-148.	0.2	98
34	The Natural History of Portal Hypertensive Gastropathy in Patients with Liver Cirrhosis and Mild Portal Hypertension. American Journal of Gastroenterology, 2004, 99, 1959-1965.	0.2	98
35	Effect of Lactitol and Lactulose Administration on the Fecal Flora in Cirrhotic Patients. Journal of Clinical Gastroenterology, 1990, 12, 433-436.	1.1	96
36	Gut-derived endotoxin stimulates factor VIII secretion from endothelial cells. Implications for hypercoagulability in cirrhosis. Journal of Hepatology, 2017, 67, 950-956.	1.8	94

#	Article	IF	Citations
37	Zinc supplementation reduces blood ammonia and increases liver ornithine transcarbamylase activity in experimental cirrhosis. Hepatology, 1992, 16, 785-789.	3.6	92
38	Depression, anxiety and alexithymia symptoms are major determinants of health related quality of life (HRQoL) in cirrhotic patients. Metabolic Brain Disease, 2013, 28, 239-243.	1.4	92
39	Optimal Nutritional Indexes in Chronic Liver Disease. Journal of Parenteral and Enteral Nutrition, 1987, 11, 130S-134S.	1.3	91
40	QT interval in patients with non-cirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepatic porto-systemic shunt. Journal of Hepatology, 2003, 38, 461-467.	1.8	88
41	The chronic use of betaâ€blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis. Liver International, 2015, 35, 362-369.	1.9	88
42	Diagnosis, treatment and survival of patients with hepatorenal syndrome: A survey on daily medical practice. Journal of Hepatology, 2011, 55, 1241-1248.	1.8	87
43	Improving the Inhibitory Control Task to Detect Minimal Hepatic Encephalopathy. Gastroenterology, 2010, 139, 510-518.e2.	0.6	85
44	Glucose intolerance and insulin resistance in cirrhosis are normalized after liver transplantation. Hepatology, 1999, 30, 649-654.	3.6	84
45	Efficacy of current guidelines for the treatment of spontaneous bacterial peritonitis in the clinical practice. World Journal of Gastroenterology, 2008, 14, 2757.	1.4	82
46	Plasma and cerebrospinal fluid amino acid patterns in hepatic encephalopathy. Digestive Diseases and Sciences, 1982, 27, 828-832.	1.1	80
47	Management of Refractory Hepatic Encephalopathy After Insertion of TIPS: Long-Term Results of Shunt Reduction With Hourglass-Shaped Balloon-Expandable Stent-Graft. American Journal of Roentgenology, 2009, 193, 1696-1702.	1.0	80
48	The Spread of Multi Drug Resistant Infections Is Leading to an Increase in the Empirical Antibiotic Treatment Failure in Cirrhosis: A Prospective Survey. PLoS ONE, 2015, 10, e0127448.	1.1	78
49	Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study. American Journal of Gastroenterology, 2002, 97, 1204-1210.	0.2	77
50	Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). Digestive and Liver Disease, 2019, 51, 190-205.	0.4	77
51	Ongoing Prothrombotic State in the Portal Circulation of Cirrhotic Patients. Thrombosis and Haemostasis, 1997, 77, 044-047.	1.8	77
52	Proton Pump Inhibitors Are Associated With Minimal and Overt Hepatic Encephalopathy and Increased Mortality in Patients With Cirrhosis. Hepatology, 2019, 70, 640-649.	3.6	74
53	Polytetrafluoroethylene-Covered Stent Grafts for TIPS Procedure: 1-Year Patency and Clinical Results. American Journal of Gastroenterology, 2004, 99, 280-285.	0.2	73
54	Increased risk of cognitive impairment in cirrhotic patients with bacterial infections. Journal of Hepatology, 2013, 59, 243-250.	1.8	72

#	Article	IF	Citations
55	Transjugular intrahepatic portosystemic shunt with expanded-polytetrafuoroethylene-covered stents in non-cirrhotic patients with portal cavernoma. Digestive and Liver Disease, 2011, 43, 78-84.	0.4	71
56	Glucose intolerance in liver cirrhosis. Metabolism: Clinical and Experimental, 1982, 31, 627-634.	1.5	70
57	Validation of automated blood cell counter for the determination of polymorphonuclear cell count in the ascitic fluid of cirrhotic patients with or without spontaneous bacterial peritonitis. American Journal of Gastroenterology, 2003, 98, 1844-1848.	0.2	67
58	Cardiac dysfunction in cirrhosis is not associated with the severity of liver disease. European Journal of Internal Medicine, 2013, 24, 172-176.	1.0	67
59	An empirical broad spectrum antibiotic therapy in healthâ€careâ€“associated infections improves survival in patients with cirrhosis: A randomized trial. Hepatology, 2016, 63, 1632-1639.	3.6	66
60	The treatment of hepatic encephalopathy. Metabolic Brain Disease, 2007, 22, 389-405.	1.4	65
61	Cognitive Impairment Predicts The Occurrence Of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt. American Journal of Gastroenterology, 2016, 111, 523-528.	0.2	63
62	Cost analysis for the prevention of variceal rebleeding: A comparison between transjugular intrahepatic portosystemic shunt and endoscopic sclerotherapy in a selected group of italian cirrhotic patients. Hepatology, 1999, 29, 1074-1077.	3.6	60
63	Vascular disorders of the liver: Recommendations from the Italian Association for the Study of the Liver (AISF) ad hoc committee. Digestive and Liver Disease, 2011, 43, 503-514.	0.4	59
64	Malnutrition is not related to alterations in energy balance in patients with stable liver cirrhosis. Clinical Nutrition, 2003, 22, 553-559.	2.3	57
65	Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference. Digestive and Liver Disease, 2016, 48, 455-467.	0.4	57
66	Cognitive Dysfunction Is Associated With Poor Socioeconomic Status in Patients With Cirrhosis: An International Multicenter Study. Clinical Gastroenterology and Hepatology, 2013, 11, 1511-1516.	2.4	55
67	The modification of quantity and quality of muscle mass improves the cognitive impairment after TIPS. Liver International, 2019, 39, 871-877.	1.9	55
68	Total and individual free fatty acid concentrations in liver cirrhosis. Metabolism: Clinical and Experimental, 1984, 33, 646-651.	1.5	54
69	Natural history of patients with non cirrhotic portal hypertension: Comparison with patients with compensated cirrhosis. Digestive and Liver Disease, 2018, 50, 839-844.	0.4	52
70	A Model for Predicting Development of Overt Hepatic Encephalopathy in Patients With Cirrhosis. Clinical Gastroenterology and Hepatology, 2015, 13, 1346-1352.	2.4	50
71	Quality of life in patients with minimal hepatic encephalopathy. World Journal of Gastroenterology, 2018, 24, 5446-5453.	1.4	50
72	Peripheral and Splanchnic Indole and Oxindole Levels in Cirrhotic Patients: A Study on the Pathophysiology of Hepatic Encephalopathy. American Journal of Gastroenterology, 2010, 105, 1374-1381.	0.2	49

#	Article	IF	Citations
73	Does malnutrition affect survival in cirrhosis?. Hepatology, 1996, 23, 1041-1046.	3.6	47
74	The burden of minimal hepatic encephalopathy: from diagnosis to therapeutic strategies. Annals of Gastroenterology, 2018, 31, 151-164.	0.4	46
75	Whole body and regional body composition analysis by dual-energy X-ray absorptiometry in cirrhotic patients. European Journal of Clinical Nutrition, 1997, 51, 810-814.	1.3	45
76	Plasma tryptophan levels and anorexia in liver cirrhosis. International Journal of Eating Disorders, 1997, 21, 181-186.	2.1	45
77	A low muscle mass increases mortality in compensated cirrhotic patients with sepsis. Liver International, 2018, 38, 851-857.	1.9	45
78	Malabsorption and nutritional abnormalities in patients with liver cirrhosis. The Italian Journal of Gastroenterology, 1990, 22, 118-23.	0.1	45
79	Drug therapy: Rifaximin1. Hepatology, 2010, 52, 1484-1488.	3.6	43
80	Previous overt hepatic encephalopathy rather than minimal hepatic encephalopathy impairs healthâ€related quality of life in cirrhotic patients. Liver International, 2011, 31, 1505-1510.	1.9	43
81	Carbon Tetrachloride-Induced Experimental Cirrhosis in the Rat: A Reappraisal of the Model. European Surgical Research, 1989, 21, 280-286.	0.6	42
82	Emerging issues in the use of transjugular intrahepatic portosystemic shunt (TIPS) for management of portal hypertension: Time to update the guidelines?. Digestive and Liver Disease, 2010, 42, 462-467.	0.4	42
83	Spontaneous porto-systemic shunts in liver cirrhosis: Clinical and therapeutical aspects. World Journal of Gastroenterology, 2020, 26, 1726-1732.	1.4	42
84	Lactitol in prevention of recurrent episodes of hepatic encephalopathy in cirrhotic patients with portal-systemic shunt. Digestive Diseases and Sciences, 1989, 34, 823-829.	1.1	39
85	A comparison of skinfold anthropometry and dual-energy X-ray absorptiometry for the evaluation of body fat in cirrhotic patients. Clinical Nutrition, 1999, 18, 349-351.	2.3	39
86	Endoscopic screening for esophageal varices in cirrhotic patients. Hepatology, 2002, 35, 501-502.	3.6	38
87	Dietary and nutritional indications in hepatic encephalopathy. Metabolic Brain Disease, 2009, 24, 211-221.	1.4	38
88	On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. Journal of Hepatology, 2021, 74, 340-349.	1.8	38
89	Relevance of Spontaneous Portosystemic Shunts Detected with CT in Patients with Cirrhosis. Radiology, 2021, 299, 133-140.	3.6	38
90	<scp>NADPH</scp> oxidaseâ€mediated platelet isoprostane overâ€production in cirrhotic patients: implication for platelet activation. Liver International, 2011, 31, 1533-1540.	1.9	37

#	Article	IF	Citations
91	Effect of Glucose and/or Branched Chain Amino Acid Infusion on Plasma Amino Acid Imbalance in Chronic Liver Failure. Journal of Parenteral and Enteral Nutrition, 1981, 5, 414-419.	1.3	36
92	Hepatic encephalopathy expands the predictivity of model for endâ€stage liver disease in liver transplant setting: Evidence by means of 2 independent cohorts. Liver Transplantation, 2016, 22, 1333-1342.	1.3	36
93	Effect of Sodium Benzoate on Blood Ammonia Response To Oral Glutamine Challenge in Cirrhotic Patients: A Note of Caution. American Journal of Gastroenterology, 2000, 95, 3574-3578.	0.2	35
94	Rifaximin therapy and hepatic encephalopathy: Pros and cons. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2012, 3, 62.	0.6	35
95	Hepatic encephalopathy: Lack of changes of Î³-aminobutyric acid content in plasma and cerebrospinal fluid. Hepatology, 1987, 7, 816-820.	3.6	34
96	Survival at 2Âyears among liver cirrhotic patients is influenced by left atrial volume and left ventricular mass. Liver International, 2017, 37, 700-706.	1.9	34
97	The additive value of sarcopenia, myosteatosis and hepatic encephalopathy in the predictivity of model for end-stage liver disease. Digestive and Liver Disease, 2019, 51, 1508-1512.	0.4	34
98	The improvement in body composition including subcutaneous and visceral fat reduces ammonia and hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Liver International, 2021, 41, 2965-2973.	1.9	33
99	A scanning electron microscopic study of liver microcirculation disarrangement in experimental rat cirrhosis. Hepatology, 1993, 17, 477-485.	3.6	31
100	Predictive Factors of Outcome After Liver Transplantation in Patients With Cirrhosis and Hepatocellular Carcinoma. Transplantation Proceedings, 2005, 37, 2535-2540.	0.3	31
101	Ascitic fluid analysis for diagnosis and monitoring of spontaneous bacterial peritonitis. World Journal of Gastroenterology, 2009, 15, 3845.	1.4	31
102	Simple tools for complex syndromes: A three-level difficulty test for hepatic encephalopathy. Digestive and Liver Disease, 2012, 44, 957-960.	0.4	31
103	Idiopathic noncirrhotic portal hypertension: current perspectives. Hepatic Medicine: Evidence and Research, 2016, Volume 8, 81-88.	0.9	31
104	Nutritional Status and Liver Transplantation. Journal of Clinical and Experimental Hepatology, 2011, 1, 190-198.	0.4	30
105	Idiopathic Non Cirrhotic Portal Hypertension and Spleno-Portal Axis Abnormalities in Patients with Severe Primary Antibody Deficiencies. Journal of Immunology Research, 2014, 2014, 1-8.	0.9	30
106	Hepatic encephalopathy: Diagnosis and management. Journal of Translational Internal Medicine, 2020, 8, 210-219.	1.0	30
107	Causes and Management of Non-cirrhotic Portal Hypertensionâ€‹. Current Gastroenterology Reports, 2020, 22, 56.	1.1	29
108	A Simplified Psychometric Evaluation for the Diagnosis of Minimal Hepatic Encephalopathy. Clinical Gastroenterology and Hepatology, 2011, 9, 613-616.e1.	2.4	26

#	Article	IF	Citations
109	No effect of albumin infusion on the prevention of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Metabolic Brain Disease, 2016, 31, 1275-1281.	1.4	26
110	Hepatitis C virus eradication with directly acting antivirals improves health-related quality of life and psychological symptoms. World Journal of Gastroenterology, 2019, 25, 6928-6938.	1.4	26
111	Phagocytosis of gadolinium chloride or zymosan induces simultaneous upregulation of hepcidin- and downregulation of hemojuvelin- and Fpn-1-gene expression in murine liver. Laboratory Investigation, 2009, 89, 1252-1260.	1.7	25
112	Modification of splenic stiffness on acoustic radiation force impulse parallels the variation of portal pressure induced by transjugular intrahepatic portosystemic shunt. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 704-709.	1.4	25
113	Improvement of nutritional status in malnourished cirrhotic patients one year after liver transplantation. European E-journal of Clinical Nutrition and Metabolism, 2011, 6, e142-e147.	0.4	24
114	AISF-SIMTI Position Paper: The appropriate use of albumin in patients with liver cirrhosis. Digestive and Liver Disease, 2016, 48, 4-15.	0.4	24
115	Radiological Intervention for Shunt Related Encephalopathy. Journal of Clinical and Experimental Hepatology, 2018, 8, 452-459.	0.4	24
116	Effect of Lactitol on Blood Ammonia Response to Oral Glutamine Challenge in Cirrhotic Patients: Evidence for An Effect of Nonabsorbable Disaccharides on Small Intestine Ammonia Generation. American Journal of Gastroenterology, 1999, 94, 3323-3327.	0.2	23
117	Sarcopenia and cognitive impairment in liver cirrhosis: A viewpoint on the clinical impact of minimal hepatic encephalopathy. World Journal of Gastroenterology, 2019, 25, 5257-5265.	1.4	23
118	Early Postprandial Energy Expenditure and Macronutrient Use After a Mixed Meal in Cirrhotic Patients. Journal of Parenteral and Enteral Nutrition, 1992, 16, 445-450.	1.3	22
119	Liver metabolic zonation and hepatic microcirculation in carbon tetrachloride-induced experimental cirrhosis. Digestive Diseases and Sciences, 1997, 42, 167-177.	1.1	21
120	The Effect of Lactulose and Lactitol Administration on Fecal Fat Excretion in Patients with Liver Cirrhosis. Journal of Clinical Gastroenterology, 1992, 15, 125-127.	1.1	20
121	Hepatic encephalopathy in patients with non-cirrhotic portal hypertension: Description, prevalence and risk factors. Digestive and Liver Disease, 2016, 48, 1072-1077.	0.4	20
122	Hepatic Encephalopathy Is Associated with Persistent Learning Impairments Despite Adequate Medical Treatment: A Multicenter, International Study. Digestive Diseases and Sciences, 2017, 62, 794-800.	1.1	20
123	Neurological and psychiatric effects of hepatitis C virus infection. World Journal of Gastroenterology, 2021, 27, 4846-4861.	1.4	20
124	Hepatic encephalopathy therapy: An overview. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2010, 1, 54.	0.6	20
125	Accuracy of the automated cell counters for management of spontaneous bacterial peritonitis. World Journal of Gastroenterology, 2008, 14, 5689.	1.4	19
126	Effect of blood ammonia elevation following oral glutamine load on the psychometric performance of cirrhotic patients. Metabolic Brain Disease, 2003, 18, 27-35.	1.4	18

#	Article	IF	Citations
127	Aminoacid imbalance and malnutrition in liver cirrhosis. Clinical Nutrition, 1985, 4, 249-253.	2.3	17
128	Increased nonoxidative glucose metabolism in idiopathic reactive hypoglycemia. Metabolism: Clinical and Experimental, 1996, 45, 606-610.	1.5	16
129	Is spontaneous bacterial peritonitis an inducer of vasopressin analogue side-effects? A case report. Digestive and Liver Disease, 2003, 35, 503-506.	0.4	15
130	Impaired nonoxidative glucose metabolism in patients with liver cirrhosis: Effects of two insulin doses. Metabolism: Clinical and Experimental, 1997, 46, 840-843.	1.5	14
131	Zinc, ammonia, and Helicobacter pylori infection in liver cirrhosis. Digestive and Liver Disease, 2000, 32, 836-838.	0.4	14
132	Prevalence and impact of sarcopenia in nonâ€cirrhotic portal hypertension. Liver International, 2019, 39, 1937-1942.	1.9	14
133	Zinc and other trace elements in liver cirrhosis. The Italian Journal of Gastroenterology, 1991, 23, 386-91.	0.1	14
134	Clinical management of type C hepatic encephalopathy. United European Gastroenterology Journal, 2020, 8, 536-543.	1.6	13
135	Clinical practice guidelines for the management of cirrhotic patients with ascites. Committee on Ascites of the Italian Association for the Study of the Liver. Italian Journal of Gastroenterology and Hepatology, 1999, 31, 626-34.	0.5	13
136	Fatty acid composition of adipose tissue in patients with chronic liver disease. Journal of Hepatology, 1986, 3, 104-110.	1.8	12
137	Small hepatic veins Buddâ€“Chiari syndrome. Journal of Thrombosis and Thrombolysis, 2014, 37, 536-539.	1.0	12
138	Hepatocellular carcinoma in cirrhotic patients with transjugular intrahepatic portosystemic shunt: A retrospective caseâ€“control study. Digestive and Liver Disease, 2014, 46, 726-730.	0.4	12
139	Risk factors for hepatic encephalopathy and mortality in cirrhosis: The role of cognitive impairment, muscle alterations and shunts. Digestive and Liver Disease, 2022, 54, 1060-1065.	0.4	12
140	Insulin and glucagon levels in fulminant hepatic failure in man. Digestive Diseases and Sciences, 1991, 36, 801-808.	1.1	11
141	Polyunsaturated fatty acids balance affects platelet NOX2 activity in patients with liver cirrhosis. Digestive and Liver Disease, 2014, 46, 632-638.	0.4	11
142	Correction of hyponatraemia in cirrhosis: Treating more than a number!. Journal of Hepatology, 2015, 62, 13-14.	1.8	11
143	A scanning electron microscopic study of liver microcirculation disarrangement in experimental rat cirrhosis. Hepatology, 1993, 17, 477-85.	3.6	11
144	Resistance to insulin suppression of plasma free fatty acids in liver cirrhosis. Journal of Endocrinological Investigation, 1990, 13, 787-795.	1.8	10

#	Article	IF	Citations
145	Impaired hepatic handling and processing of lysophosphatidylcholine in rats with liver cirrhosis. Gastroenterology, 1991, 101, 228-237.	0.6	10
146	Ticlopidine-induced cholestasis. European Journal of Gastroenterology and Hepatology, 1994, 6, 943-950.	0.8	10
147	D-Lactic acidosis 25 years after bariatric surgery due to Salmonella enteritidis. Nutrition, 2012, 28, 108-111.	1.1	10
148	Portal Hypertension and Ascites: Patient-and Population-centered Clinical Practice Guidelines by the Italian Association for the Study of the Liver (AISF). Digestive and Liver Disease, 2021, 53, 1089-1104.	0.4	10
149	Ammonia and the Muscle: An Emerging Point of View on Hepatic Encephalopathy. Journal of Clinical Medicine, 2022, 11, 611.	1.0	10
150	Gut liver muscle brain axis: A comprehensive viewpoint on prognosis in cirrhosis. Journal of Hepatology, 2022, 77, 262-263.	1.8	10
151	Lactitol in the treatment of chronic hepatic encephalopathy--a randomized cross-over comparison with lactulose. Hepato-Gastroenterology, 1990, 37, 524-7.	0.5	10
152	Nutritional status in liver cirrhosis. The Italian Journal of Gastroenterology, 1993, 25, 400-1.	0.1	10
153	Intractable Hepatic Encephalopathy After Tips with Polytetrafluoroethylene-covered Stent-Graft. Scandinavian Journal of Gastroenterology, 2003, 38, 570-572.	0.6	9
154	Reply to Dr. Andusâ€™ letter. Clinical Nutrition, 2007, 26, 273-274.	2.3	9
155	Management of Hepatic Encephalopathy Not Responsive to First-Line Treatments. Current Treatment Options in Gastroenterology, 2018, 16, 253-259.	0.3	9
156	How to Design a Multicenter Clinical Trial in Hepatic Encephalopathy. Journal of Clinical and Experimental Hepatology, 2019, 9, 137-145.	0.4	9
157	IS THE BLOOD-BRAIN BARRIER REALLY INTACT IN PORTAL-SYSTEMIC ENCEPHALOPATHY?. Lancet, The, 1981, 317, 1367.	6.3	8
158	Clotting Activation after Transjugular Intrahepatic Portosystemic Stent Shunt. Thrombosis and Haemostasis, 1999, 81, 711-714.	1.8	8
159	Incidence of portal hypertension in patients exposed to oxaliplatin. Digestive and Liver Disease, 2019, 51, 1348-1350.	0.4	8
160	Low Interleukin-22 Binding Protein Is Associated With High Mortality in Alcoholic Hepatitis and Modulates Interleukin-22 Receptor Expression. Clinical and Translational Gastroenterology, 2020, 11, e00197.	1.3	8
161	Risk of falls in patients with cirrhosis evaluated by timed up and go test: Does muscle or brain matter more?. Digestive and Liver Disease, 2022, 54, 371-377.	0.4	8
162	Branched-Chain Amino Acids in the Treatment of Severe Hepatic Encephalopathy. , 1984, , 335-344.		8

#	Article	IF	Citations
163	Is porto sinusoidal vascular disease to be actively searched in patients with portal vein thrombosis?. World Journal of Hepatology, 2019, 11, 613-618.	0.8	8
164	Oxidative Stress in the Pathogenesis of Antiphospholipid Syndrome: Implications for the Atherothrombotic Process. Antioxidants, 2021, 10, 1790.	2.2	8
165	Increased energy expenditure in cirrhotic patients with hepatocellular carcinoma. Nutrition, 1992, 8, 321-5.	1.1	8
166	The hepatic microcirculation in experimental cirrhosis. A scanning electron microscopy study of microcorrosion casts. Scanning Microscopy, 1991, 5, 495-502; discussion 502-3.	0.3	8
167	Use of the stable isotope 65Cu test for the screening of Wilson's disease in a family with two affected members. Italian Journal of Gastroenterology and Hepatology, 1998, 30, 270-5.	0.5	8
168	Clinical nutrition practice in Italian Gastroenterology Units. Digestive and Liver Disease, 2000, 32, 473-479.	0.4	7
169	Portal Hypertension Related to Schistosomiasis Treated With a Transjugular Intrahepatic Portosystemic Shunt. Journal of Clinical Gastroenterology, 2016, 50, 608-610.	1.1	7
170	A cost analysis of a broad-spectrum antibiotic therapy in the empirical treatment of health care-associated infections in cirrhotic patients. ClinicoEconomics and Outcomes Research, 2017, Volume 9, 385-390.	0.7	7
171	Paroxysmal nocturnal hemoglobinuria and vascular liver disease: Eculizumab therapy decreases mortality and thrombotic complications. American Journal of Hematology, 2022, 97, 431-439.	2.0	7
172	Nonabsorbable disaccharides plus neomycin in hepatic encephalopathy: Do they enhance each other?. Hepatology, 1990, 12, 368-370.	3.6	6
173	Intravascular hemolysis and transjugular intrahepatic portosystemic stent shunt. Journal of Hepatology, 1994, 20, 152-153.	1.8	6
174	P473 BACTERIAL INFECTIONS IN CIRRHOTIC PATIENTS: RISK FACTORS AND RATE OF FAILURE OF THE EMPIRICAL ANTIBIOTIC THERAPY. Journal of Hepatology, 2014, 60, S227.	1.8	6
175	Management of hepatic encephalopathy as an inpatient. Clinical Liver Disease, 2015, 5, 79-82.	1.0	6
176	Zinc supplementation in experimental liver cirrhosis: a morphological, structural and ultrastructural study. International Journal of Experimental Pathology, 1993, 74, 463-9.	0.6	6
177	Circadian rhythmicity of plasma amino acid variations in healthy subjects. Recenti Progressi in Medicina, 1989, 80, 591-3.	0.8	6
178	Cognitive Impairement in Non-Cirrhotic Portal Hypertension: Highlights on Physiopathology, Diagnosis and Management. Journal of Clinical Medicine, 2022, 11, 101.	1.0	6
179	Is hyperammonemia really the true cause of altered neuropsychology, brain MR spectroscopy and magnetization transfer after an oral amino acid load in cirrhosis?. Hepatology, 2003, 38, 777-777.	3.6	5
180	Can an incomplete stent expansion modulate the effects of TIPS?. Journal of Gastroenterology, 2010, 45, 346-347.	2.3	5

#	Article	IF	Citations
181	Albumin infusion in cirrhotic patients with infections other than spontaneous bacterial peritonitis: End of the story?. Journal of Hepatology, 2015, 63, 767-768.	1.8	5
182	PS-083-Serum albumin concentration as guide for long-term albumin treatment in patients with cirrhosis and uncomplicated ascites: Lessons from the ANSWER study. Journal of Hepatology, 2019, 70, e53.	1.8	5
183	Identifying Patients at High Risk of Developing Non-Cirrhotic Portal Hypertension. Hepatic Medicine: Evidence and Research, 2021, Volume 13, 105-111.	0.9	5
184	Simultaneous radioenzymatic determination of phenylethylamine, phenylethanolamine, tyramine and octopamine in plasma of patients with hepatic encephalopathy. Clinical Biochemistry, 1981, 14, 187-190.	0.8	4
185	TIPS versus paracentesis in the treatment of refractory ascites: Preliminary results of a randomized controlled trial. Gastroenterology, 2000, 118, A980.	0.6	4
186	Emerging drugs for hepatic encephalopathy. Expert Opinion on Emerging Drugs, 2009, 14, 537-549.	1.0	4
187	Hepatic encephalopathy: you should only comment on what you have actually measured. Journal of Gastroenterology, 2010, 45, 342-343.	2.3	4
188	Letter to the Editor: Liver Stiffness in Noncirrhotic Portal Hypertension: The Devil Is in the Diagnosis. Hepatology, 2019, 70, 444-445.	3.6	4
189	Nutrition Assessment and Management in Patients with Cirrhosis and Cognitive Impairment: A Comprehensive Review of Literature. Journal of Clinical Medicine, 2022, 11, 2842.	1.0	4
190	Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: Still a major problem. Hepatology, 2010, 51, 2237-2238.	3.6	3
191	Interaction between infection and hepatic encephalopathy. Journal of Hepatology, 2015, 62, 746-747.	1.8	3
192	Long-term use of human albumin for the treatment of ascites in patients with hepatic cirrhosis: The interim analysis of the ANSWER study. Digestive and Liver Disease, 2015, 47, e6.	0.4	3
193	Erectile dysfunction in patients with liver cirrhosis. Digestive and Liver Disease, 2019, 51, 856-857.	0.4	3
194	Session 1: Definition of Key Eventsâ€“ Last Attempt?. , 0, , 11-39.		3
195	TIPS for patients awaiting orthotopic liver transplantation. Liver Transplantation, 2003, 9, 999-1000.	1.3	2
196	Do We Really Need Alternatives to Polymorphonuclear Cells Counting in Ascitic Fluid?. Gastroenterology, 2009, 136, 728-729.	0.6	2
197	31 CLINICAL EFFICACY OF TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT CREATED WITH COVERED STENTS WITH DIFFERENT DIAMETERS: RESULTS OF A RANDOMIZED CONTROLLED TRIAL. Digestive and Liver Disease, 2010, 42, S13.	0.4	2
198	Proton pump inhibitors increase the risk of minimal and overt hepatic encephalopathy and they are associated with high mortality in cirrhotic patients. Journal of Hepatology, 2018, 68, S732-S733.	1.8	2

#	Article	IF	Citations
199	Long-term albumin administration in patients with cirrhosis and uncomplicated ascites: the use of serum albumin concentration for personalizing treatment. Digestive and Liver Disease, 2019, 51, e9.	0.4	2
200	Hepatic Encephalopathy in the 21st Century: Still an Emerging Topic. Journal of Clinical Medicine, 2021, 10, 298.	1.0	2
201	Small hepatic veins Budd-Chiari syndrome and paroxysmal nocturnal hemoglobinuria - The association of two rare entities: a case report. Pathologica, 2020, 112, 102-104.	1.3	2
202	Clotting activation after transjugular intrahepatic portosystemic stent shunt. Thrombosis and Haemostasis, 1999, 81, 711-4.	1.8	2
203	Intractable hepatic encephalopathy after tips with polytetrafluoroethylene-covered stent-graft. Scandinavian Journal of Gastroenterology, 2003, 38, 570-2.	0.6	2
204	Editorial: infections and hepatic encephalopathyâ€“does the chicken or the egg come FIRST? A novel perspective at the horizon. Alimentary Pharmacology and Therapeutics, 2022, 55, 744-745.	1.9	2
205	Composition of Free Fatty Acids and Adipose Tissue Triglycerides in Portacaval Shunted Rats. European Surgical Research, 1987, 19, 151-158.	0.6	1
206	Preliminary results of a randomised controlled trials in the prevention of early post-tips hepatic encephalopathy: a comparison between rifaximin and lactitol. Journal of Hepatology, 2002, 36, 205.	1.8	1
207	PTFE-covered stent-grafts for tips procedure: One-year patency and clinical results. Journal of Hepatology, 2003, 38, 66.	1.8	1
208	220 Randomised controlled trial for the prevention of hepatic encephalopathy after transjugular intrahepatic porto-systemic shunt (TIPS): Comparison between lactitol, rifaximin and no treatment. Journal of Hepatology, 2004, 40, 70-71.	1.8	1
209	296 EFFICACY OF ASCITES CLUB GUIDELINES FOR THE TREATMENT OF SPONTANEOUS BACTERIAL PERITONITIS IN THE CLINICAL PRACTICE. Journal of Hepatology, 2008, 48, S118.	1.8	1
210	P.234 CLINICAL EFFICACY OF TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT CREATED WITH COVERED STENTS WITH DIFFERENT DIAMETERS: RESULTS OF A RANDOMIZED CONTROLLED TRIAL. Digestive and Liver Disease, 2010, 42, S183-S184.	0.4	1
211	Does the gut microbiota modulate the inflammatory state in cirrhotic host?. Digestive and Liver Disease, 2014, 46, e34.	0.4	1
212	OC.13.9: Sarcopenia Represents a Risk Factor for the Development of Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt. Digestive and Liver Disease, 2017, 49, e115-e116.	0.4	1
213	Small-for-flow liver failure after extended hepatectomy: hot questions and an update. Gastroenterology Insights, 2017, 8, .	0.7	1
214	May sarcopenia and/or hepatic encephalopathy improve the predictivity of model for end-stage liver disease?. Journal of Hepatology, 2018, 68, 1324-1325.	1.8	1
215	Prediction of hepatic encephalopathy: Why disregard wellâ€known risk factors?. Hepatology, 2018, 67, 1637-1637.	3.6	1
216	The amelioration of muscle wasting leads to the improvement of cognitive impairment after transjugular intrahepatic portosystemic shunt: A proof of concept that sarcopenia and hepatic encephalopathy are causally related. Journal of Hepatology, 2018, 68, S700-S701.	1.8	1

#	Article	IF	Citations
217	PS-018-Paroxysmal nocturnal hemoglobinuria and Budd Chiari syndrome: Impact of Eculizumab therapy on survival and liver outcome in 54 patients: A multicentric valdig study. Journal of Hepatology, 2019, 70, e14.	1.8	1
218	Reply. Hepatology, 2019, 70, 762-763.	3.6	1
219	P: 25â€ƒMuscle Alterations Are Associated With Minimal and Overt Hepatic Encephalopathy in Patients With Liver Cirrhosis. American Journal of Gastroenterology, 2019, 114, S13-S13.	0.2	1
220	Long-term albumin therapy is not futile in patients with cirrhosis and uncomplicated ascites not normalizing on-treatment serum albumin concentration. Digestive and Liver Disease, 2020, 52, e57-e58.	0.4	1
221	Nutrition and Hepatic Encephalopathy. , 2012, , 199-209.		1
222	TIPS: Refractory Ascites and Encephalopathy. Medical Radiology, 2000, , 297-303.	0.0	1
223	A scanning electron microscopic study of liver microcirculation disarrangement in experimental rat cirrhosis. Hepatology, 1993, 17, 477-485.	3.6	1
224	Macronutrient oxidation in liver disease. The Italian Journal of Gastroenterology, 1993, 25, 272-5.	0.1	1
225	Effects of Branched Chain Amino Acids on Biochemical Variables and Clinical Symptoms of Hepatic Encephalopathy*. , 1983, , 400-411.		0
226	The Pros and the Cons of the Amino Acid Neurotransmitter Hypothesis. , 1984, , 460-471.		0
227	From meetings. Research in Clinic and Laboratory, 1988, 18, 330-373.	0.3	0
228	Prevalence of chronic liver disease in northern Italy. Hepatology, 1996, 23, 1710-1712.	3.6	0
229	Energy expenditure and caloric intake in patients with stable cirrhosis with or without malnutrition. Gastroenterology, 2000, 118, A1482.	0.6	0
230	Sodium benzoate increases blood ammonia levels in cirrhotic patients. Gastroenterology, 2000, 118, A981.	0.6	0
231	Iron depletion and interferon (IFN) therapy: A multicenter, randomized trial in â€œnaiveâ€•patients with chronic hepatitis C. Journal of Hepatology, 2000, 32, 114.	1.8	0
232	Serum leptin levels in cirrhosis. Gastroenterology, 2000, 118, A1469.	0.6	0
233	Leptin in cirrhotic patients. Journal of Hepatology, 2000, 32, 213.	1.8	0
234	Accuracy of the mayo clinic model to predict survival in patients with elective tips. Journal of Hepatology, 2001, 34, 31.	1.8	0

#	Article	IF	Citations
235	Validation of a model predicting survival in patients with tips. Journal of Hepatology, 2001, 34, 52.	1.8	0
236	Bone density and nutritional assessment in cirrhotic patients. Journal of Hepatology, 2001, 34, 76.	1.8	0
237	Response to Drs. Piscaglia et al.. American Journal of Gastroenterology, 2001, 96, 2504-2505.	0.2	0
238	Iron reduction and sustained response to interferon-Î± therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study. American Journal of Gastroenterology, 2002, 97, 1204-1210.	0.2	0
239	Hyperdynamic circulation after tips implantation: its effects on neurohumoral system. Journal of Hepatology, 2002, 36, 201-202.	1.8	0
240	Role of the determination of partial pressure of ammonia in cirrhotic patients with hepatic encephalopathy. Journal of Hepatology, 2002, 36, 207.	1.8	0
241	Prevalence and clinical relevance of spontaneous porto-systemic shunts in cirrhotic patients with recurrent hepatic encephalopathy: A case control study. Journal of Hepatology, 2003, 38, 58.	1.8	0
242	204 Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt (tips): PTFE-covered stent grafts versus bare stents. Journal of Hepatology, 2006, 44, S84.	1.8	0
243	Does nutritional status influence the outcome in patients undergoing liver transplantation in the â€œMELDâ€•era?. Digestive and Liver Disease, 2007, 39, A41.	0.4	0
244	Short-term changes in nutritional status, energy expenditure, dietary intake in patients undergoing liver transplantation. Digestive and Liver Disease, 2007, 39, A41.	0.4	0
245	PA.187 SEQUENTIAL CHANGES IN NUTRITIONAL STATUS, ENERGY EXPENDITURE, DIETARY INTAKE DURING THE FIRST SIX MONTHS AFTER LIVER TRANSPLANTATION. Digestive and Liver Disease, 2008, 40, S144.	0.4	0
246	Transjugular intrahepatic portosystemic shunt (TIPS) is feasible in non-cirrhotic patients with cavernomatous tranformation of the portal vein. Digestive and Liver Disease, 2008, 40, A9-A10.	0.4	0
247	Peripheral and splanchnic indole and oxindole levels in cirrhotic patients: A study on the pathophysiology of hepatic encephalopathy. Digestive and Liver Disease, 2009, 41, A24-A25.	0.4	0
248	CS.1.4 A PROSPECTIVE ITALIAN SURVEY ON HEPATORENAL SYNDROME. Digestive and Liver Disease, 2010, 42, S62-S63.	0.4	0
249	P.139 INCIDENCE OF HEPATOCELLULAR CARCINOMA IN A POPULATION OF CIRRHOTIC PATIENTS TREATED WITH TIPS: A CASE-CONTROL STUDY. Digestive and Liver Disease, 2010, 42, S152.	0.4	0
250	P.146 BACTERIAL INFECTIONS AND SEPSIS ACUTELY DETERIORATE LIVER FUNCTION IN CIRRHOTIC PATIENTS: A PROSPECTIVE STUDY. Digestive and Liver Disease, 2010, 42, S154.	0.4	0
251	P.147 MELD, PROTEIN MALNUTRITION AND PREVIOUS INFECTIONS ARE PREDICTORS OF BACTERIAL INFECTIONS AND SEPSIS IN CIRRHOTIC PATIENTS. Digestive and Liver Disease, 2010, 42, S154-S155.	0.4	0
252	P.235 INHIBITORY CONTROL TEST DOES NOT IDENTIFY THE PATIENTS AT RISK OF DEVELOPING OVERT HE IN AN ITALIAN POPULATION OF CIRRHOTIC PATIENTS. Digestive and Liver Disease, 2010, 42, S184.	0.4	0

#	Article	IF	Citations
253	P.236 MINIMAL HEPATIC ENCEPHALOPATHY (MHE): SIMPLIFIED DIAGNOSIS AND RELATIONSHIP WITH THE DEVELOPMENT OF OVERT HEPATIC ENCEPHALOPATHY (OHE). Digestive and Liver Disease, 2010, 42, S184-S185.	0.4	0
254	T.N.9 MINIMAL HEPATIC ENCEPHALOPATHY (MHE): SIMPLIFIED DIAGNOSIS AND RELATIONSHIP WITH THE DEVELOPMENT OF OVERT HEPATIC ENCEPHALOPATHY (OHE). Digestive and Liver Disease, 2010, 42, S18.	0.4	0
255	F.N.8 INHIBITORY CONTROL TEST DOES NOT IDENTIFY THE PATIENTS AT RISK OF DEVELOPING OVERT HEPATIC ENCEPHALOPATHY (HE) IN AN ITALIAN POPULATION OF CIRRHOTIC PATIENTS. Digestive and Liver Disease, 2010, 42, S35-S36.	0.4	0
256	Small Intestine Lesion in Portal Hypertension: Pre and Post Tips. Gastroenterology, 2011, 140, S-766-S-767.	0.6	0
257	Videocapsule Endoscopy in Portal Hypertension. Gastroenterology, 2011, 140, S-754-S-755.	0.6	0
258	F-16 Videocapsule endoscopy in portal hypertension: Seek till you find. Digestive and Liver Disease, 2011, 43, S97.	0.4	0
259	P.1.276: ALBUMIN ADMINISTRATION SUPPORTS CARDIAC OUTPUT IN CIRRHOTIC PATIENTS AFTER TOTAL PARACENTESIS. Digestive and Liver Disease, 2011, 43, S240.	0.4	0
260	598 IN VITRO EFFECT OF n-6/n-3 POLYUNSATURATED FATTY ACIDS ON PLATELET NOX2-MEDIATED OXIDATIVE STRESS IN LIVER CIRRHOSIS. Journal of Hepatology, 2013, 58, S244-S245.	1.8	0
261	P.16.13 PROTEIN MALNUTRITION IS ASSOCIATED TO A WORSE PROGNOSIS IN PATIENTS WITH CIRRHOSIS CHILD Aâ€“B AND SEPSIS. Digestive and Liver Disease, 2014, 46, S118.	0.4	0
262	Reply. Clinical Gastroenterology and Hepatology, 2014, 12, 707-708.	2.4	0
263	Erratum to â€œVascular disorders of the liver: Recommendations from the Italian Association for the Study of the Liver (AISF) ad hoc committeeâ€•[Digest. Liver Dis. 43 (7) (2011) 503â€“514]. Digestive and Liver Disease, 2014, 46, 388.	0.4	0
264	PC.01.7 BACTERIAL INFECTIONS IN CIRRHOTIC PATIENTS: RISK FACTORS AND RATE OF FAILURE OF THE EMPIRICAL ANTIBIOTIC THERAPY. Digestive and Liver Disease, 2014, 46, S3.	0.4	0
265	3D-Speckle Tracking Echocardiography in cirrhotic patients: A possible tool for the diagnosis of cirrhotic cardiomyopathy. Digestive and Liver Disease, 2014, 46, e62.	0.4	0
266	P513 A SIMPLE MODEL FOR THE PREDICTION OF OVERT HEPATIC ENCEPHALOPATHY IN CIRRHOTIC PATIENTS: RESULTS OF A PROSPECTIVE OBSERVATIONAL STUDY AND VALIDATION IN AN INDEPENDENT COHORT. Journal of Hepatology, 2014, 60, S240-S241.	1.8	0
267	P474 CLINICAL OUTCOMES OF PATIENTS WITH PORTAL HYPERTENSION NOT DUE TO CIRRHOSIS: A SINGLE-CENTRE EXPERIENCE. Journal of Hepatology, 2014, 60, S227.	1.8	0
268	Betaâ€blockers in patients with cirrhosis and infections: don't blame too soon!. Liver International, 2015, 35, 1778-1779.	1.9	0
269	Cognitive Impairment Predicts the Occurrence of Hepatic Encephalopathy after Transjugular Intrahepatic Portosysthemic Shunt. Journal of Hepatology, 2016, 64, S287.	1.8	0
270	Is Protein Malnutrition a Negative Prognostic Factor in Compensated Cirrhotic Patients? A Retrospective Analysis Answering to the Proposal of the Italian Consensus on Portal Hypertension (Baveno VI). Journal of Hepatology, 2016, 64, S253.	1.8	0

#	Article	IF	Citations
271	Hepatic Encephalopathy is Associated with Persistent Learning Impairments despite Adequate Medical Treatment: A Multi-Center, International Study. Journal of Hepatology, 2016, 64, S286-S287.	1.8	0
272	OC.03.5 COGNITIVE IMPAIRMENT PREDICTS THE OCCURRENCE OF HEPATIC ENCEPHALOPATHY AFTER TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT. Digestive and Liver Disease, 2016, 48, e81.	0.4	0
273	P.01.6 HEPATIC ENCEPHALOPATHY IS ASSOCIATED WITH PERSISTENT COGNITIVE DEFICITS DESPITE ADEQUATE MEDICAL TREATMENT: A MULTI-CENTER, INTERNATIONAL STUDY. Digestive and Liver Disease, 2016, 48, e131-e132.	0.4	0
274	SAT-088-Sarcopenia and Myosteatosis are associated with minimal and overt hepatic encephalopathy in patients with liver cirrhosis. Journal of Hepatology, 2019, 70, e666-e667.	1.8	0
275	Clinical presentation and etiological spectrum of idiopathic non-cirrhotic portal hypertension (INCPH): data from the Italian Registry. Digestive and Liver Disease, 2019, 51, e49.	0.4	0
276	P: 26â€ƒThe Modification of Quantity and Quality of Muscle Mass Improves the Cognitive Impairment After TIPS. American Journal of Gastroenterology, 2019, 114, S14-S14.	0.2	0
277	Long-term albumin administration is not futile in patients with cirrhosis and uncomplicated ascites not normalizing serum albumin concentration with treatment. Journal of Hepatology, 2020, 73, S738.	1.8	0
278	JAK2 (V617F) Mutation Levels and Marrow Fibrosis in Patients Affected by Budd-Chiari Syndrome and Non-Cirrhotic Extra-Hepatic Portal Vein Obstruction.. Blood, 2007, 110, 4652-4652.	0.6	0
279	Minimal hepatic encephalopathy and sleep disorders in patients with cirrhosis: Which comes first?. Saudi Journal of Gastroenterology, 2020, 26, 111.	0.5	0
280	Letter to the editor: Episodicâ€precipitantâ€“induced hepatic encephalopathy treatment: Look at new and old precipitants!. Hepatology, 2022, 75, 1065-1066.	3.6	0
281	First and second generation non absorbable disaccharides in the treatment of hepatic encephalopathy. The Italian Journal of Gastroenterology, 1990, 22, 365-7.	0.1	0
282	Transjugular intra-hepatic portosystemic shunt (TIPS) in elderly patients: preliminary analysis of a multicenter retrospective cohort.. Digestive and Liver Disease, 2022, 54, S7-S8.	0.4	0
283	Episodic Precipitantâ€“induced Hepatic Encephalopathy Treatment. Journal of Clinical Gastroenterology, 2022, 56, 192-193.	1.1	0
284	T.08.9 GAIT DISORDERS IN CIRRHOTIC PATIENTS WITH AND WITHOUT COGNITIVE IMPAIRMENT: PRELIMINARY RESULTS OF A PROSPECTIVE STUDY. Digestive and Liver Disease, 2022, 54, S150-S151.	0.4	0
285	The application of Pancreatitis Activity Score System in clinical practice: an Italian experience. European Journal of Gastroenterology and Hepatology, 2022, 34, 724-725.	0.8	0
286	Prevalence of chronic liver disease in northern Italy. Hepatology, 1996, 23, 1710-1712.	3.6	0